BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22345123)

  • 1. Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.
    Klaasen R; Wijbrandts CA; van Kuijk AW; Pots D; Gerlag DM; Tak PP
    Ann Rheum Dis; 2012 Jul; 71(7):1260-1. PubMed ID: 22345123
    [No Abstract]   [Full Text] [Related]  

  • 2. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
    Toh ML; Marotte H; Blond JL; Jhumka U; Eljaafari A; Mougin B; Miossec P
    Arthritis Rheum; 2006 Jul; 54(7):2109-18. PubMed ID: 16802346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.
    van Kuijk AW; Wijbrandts CA; Vinkenoog M; Zheng TS; Reedquist KA; Tak PP
    Ann Rheum Dis; 2010 Jan; 69(1):301-4. PubMed ID: 19147618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoid aggregation is not lymphoid neogenesis: comment on the article by Klaasen et al.
    Cañete JD; Pablos JL
    Arthritis Rheum; 2010 Sep; 62(9):2825-6. PubMed ID: 20496427
    [No Abstract]   [Full Text] [Related]  

  • 7. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
    Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
    Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.
    Sundberg E; Grundtman C; Af Klint E; Lindberg J; Ernestam S; Ulfgren AK; Harris HE; Andersson U
    Arthritis Res Ther; 2008; 10(2):R33. PubMed ID: 18346273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.
    Tutuncu Z; Kavanaugh A; Zvaifler N; Corr M; Deutsch R; Boyle D
    Arthritis Rheum; 2005 Sep; 52(9):2693-6. PubMed ID: 16142749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis.
    Immonen K; Kauppi M; Hakala M
    Scand J Rheumatol; 2011 May; 40(3):236-8. PubMed ID: 21231814
    [No Abstract]   [Full Text] [Related]  

  • 15. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.
    van Kuijk AW; Gerlag DM; Vos K; Wolbink G; de Groot M; de Rie MA; Zwinderman AH; Dijkmans BA; Tak PP
    Ann Rheum Dis; 2009 Aug; 68(8):1303-9. PubMed ID: 18647851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of disease-modifying antirheumatic drug treatment on the expression of RANKL and osteoprotegerin in synovial tissue: comment on the article by Haynes et al.
    Catrina AI; Klareskog L
    Arthritis Rheum; 2008 Nov; 59(11):1685; author reply 1685-6. PubMed ID: 18975354
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of a new immunohistology scoring system (IH score): analysis of TNF-α in synovium related to disease activity score in infliximab-treated patients with rheumatoid arthritis.
    Kanbe K; Hara R; Chiba J; Inoue Y; Taguchi M; Tanaka Y
    Mod Rheumatol; 2014 Nov; 24(6):910-4. PubMed ID: 24670132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.